Amgen Inc.

Ana Elena Minatti

Jonathan Dante Low

Qiufen May Xue

Patricia Lopez

Jennifer Rebecca Allen

Brian Alan Lanman

Vu Van Ma

Jian Jeffrey Chen

Ning Chen

Albert Kudzovi Amegadzie

Nobuko Nishimura

Ryan D White

Victor J Cee

Yuan Cheng

Nuria A Tamayo

Alexander J Pickrell

Ryan Paul Wurz

Clifford Goodman

Anthony B Reed

Shon Booker

Michael J Frohn

Hui-Ling Wang

Paul E Harrington

Thomas T Nguyen

Qingyian Liu

Wenge Zhong

Ted Charles Judd

Aaron C Siegmund

Matthew Paul Bourbeau

James A Brown

Longbin Liu

John Gordon Allen

Kexue Li

Mary Walton

Robert Michael Rzasa

Wenyuan Qian

Shannon Rumfelt

Oleg Epstein

Christopher Michael Tegley

Angel Guzman-Perez

Sean P Brown

Markian Myroslaw Stec

Bryant Yang

Jason Brooks Human

Kelvin C Sham

Yunxiao Li

Xiao Mei Zheng

Matthew M Weiss

Matthew R Kaller

Liping H Pettus

David John Kopecky

Youngsook Shin

Todd J Kohn

Joshua Taygerly

Kate Ashton

Abhisek Banerjee

Margaret Chu-Moyer

Iain Lingard

Kevin Chao Yang

Isaac E Marx

Thomas Dineen

Adrian Leonard Smith

Nick A Paras

Timothy Powers

Michela Beltrani

Teodora P Damyanova

Paolo Vincetti

Mary Catherine Walton Cabrera

Vinod Francis Patel

Mark Henry Norman

Stephen A Hitchcock

Laurie B Schenkel

Michael D Bartberger

Alan C Cheng

Lei Jia

Hanh Nho Nguyen

Randall W Hungate

Charles Kreiman

Thomas Nixey

Karina Romero

James R Manning

Erin F DiMauro

Deborah Choquette

Michele Potashman

Philip R Olivieri

Vijay Keshav Gore

Zihao Hua

John Stellwagen

Corey Reeves

Alfonso Pozzan

Federica Tonelli

Richard T Lewis

Giulia Lattanzi

Sabrina Tassini

Kelvin Sham

James Brown

Adrian L Smith

The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

KIF18A inhibitors

The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula I. wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

KRAS G12C inhibitors and methods of using the same

Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Substituted piperazines as KRAS G12C inhibitors

Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

Inhibitors of KRAS G12C and methods of using the same

The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase ('D5D'). The compounds have a general Formula I wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use

Provided herein are methods of using KRAS G12C inhibitors. These methods of using the inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. 

Macrocyclic compounds that inhibit MCL-1 protein

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibits MCL-1 protein

Growing community of inventors

Santa Monica, CA, United States of America

Ana Elena Minatti